Recently, van Raalte et al performed a randomized, placebo-controlled, double-blind, crossover study in eight healthy men, to understand whether treatment with the GLP-1 agonist, exenatide could prevent glucocorticoids-induced glucose intolerance. This evidence concerns the gene GCG and Glucose intolerance.